Inflammatory Skin Diseases
Aimilios Lallas, Zoe Apalla, Elizabeth Lazaridou, Dimitrios Ioannides, Theodosia Gkentsidi, Christina Fotiadou, Theocharis-Nektarios Kirtsios, Eirini Kyrmanidou, Konstantinos Lallas, Chryssoula Papageorgiou in Dermatoscopy A–Z, 2019
Several dermatoscopic patterns for lymphomatoid papulosis (LyP) have been described depending on the stage of evolution of each lesion. In early lesions, the vascular pattern is predominant and consists of dotted or tortuous/irregular vessels over an erythematous background. Purpuric spots are common at this stage. Progressively, scales become more prominent, and the vessels are limited at the periphery. In hyperkeratotic lesions, white or yellow scales cover the central part of the papules, while in a necrotic lesion, the main dermatoscopic feature is the central brownish-yellow crusts (Figure 6.46). Finally, postinflammatory pigmentation, seen as brown structureless areas, typifies healing lesions.
Principles of Clinical Diagnosis
Susan Bayliss Mallory, Alanna Bree, Peggy Chern in Illustrated Manual of Pediatric Dermatology, 2005
Romani J, Puig L, Fernandez-Figueras MT, de Moragas JM. Pityriasis lichenoides in children: clinicopathologic review of 22 patients. Pediatr Dermatol 1998; 15: 11–16 Lymphomatoid papulosis
Small molecule inhibitors for cutaneous T-cell lymphomas
Published in Expert Opinion on Orphan Drugs, 2018
Cutaneous T-cell lymphomas (CTCLs) are a group of non-Hodgkin’s T-cell lymphomas showing a wide variety of clinical, histopathological, and immunohistochemical findings [1]. Mycosis fungoides, primary cutaneous CD30+ lymphoproliferative disorders, and Sezary syndrome are the most common subtypes of CTCLs [2,3]. Mycosis fungoides represents nearly 50% of all primary CTCLs. In the initial stages, mycosis fungoides presents as slowly progressing erythematous, round, oval, or arciform patches/plaques and its clinical course is generally considered indolent. In about 30% of patients, mycosis fungoides is characterized by an aggressive clinical behavior with multiple nodular/tumor lesions and extracutaneous spread. Sezary syndrome is a rare and more aggressive subtype of CTCL characterized by a generalized exfoliative erythema with severe pruritus and disseminated disease into the blood and lymph nodes [3]. Primary cutaneous CD30+ lymphoproliferative disorders represent about 25% of all CTCLs and include a spectrum of CD30+ cutaneous lymphomas ranging from primary cutaneous anaplastic large cell lymphoma to lymphomatoid papulosis. Primary cutaneous anaplastic large cell lymphoma presents with solitary or localized nodules, sometimes with ulceration and rarely shows extracutaneous involvement during its clinical course [4]. Lymphomatoid papulosis is characterized by an indolent and self-healing diffuse papulo-nodular eruption, generally involving trunk and extremities [4].
Cutaneous B-Cell Pseudolymphoma (Lymphocytoma Cutis) of the Earlobe: A Poorly Recognized Complication of Ear Piercing in Children
Published in Fetal and Pediatric Pathology, 2022
Jonathan C Slack, Kyle C Kurek, Frankie O G Fraulin, Marie-Anne Brundler
CPL constitutes a heterogeneous group of lymphoproliferative processes that can mimic cutaneous lymphoma. Morphologically, two major subtypes are recognized based on which lymphocyte lineage is predominant. Clinical, histologic, and immunophenotypic features that distinguish the two subtypes are summarized in Table 1. However, considerable overlap exists between the two subtypes and in some instances also with malignant lymphoma. Some variants of CPL, most notably lymphomatoid papulosis, can exhibit architectural and cytological atypia, immunohistochemical abnormalities, and may be monoclonal; thus are considered by some to represent a precursor to lymphoma [1].
Topical methotrexate in dermatology: a review of the literature
Published in Journal of Dermatological Treatment, 2022
Divya Aickara, Arjun M. Bashyam, Rita O. Pichardo, Steven R. Feldman
In one patient, topical MTX resolved lymphomatoid papulosis. The patient created his own formulation by moistening a 2.5 mg tablet of MTX with tap water and rubbed the tablet on gauze until the gauze turned orange. He placed the gauze with a bandage over any newly formed papules daily. He used approximately one third of a tablet (0.83 mg) per lesion per day (32).
Related Knowledge Centers
- Lymphoma
- Skin Condition
- Anaplastic Large-Cell Lymphoma
- Methotrexate
- Cutaneous T-Cell Lymphoma
- Parapsoriasis
- Secondary Cutaneous Cd30+ Large-Cell Lymphoma